Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2005-02-15
2005-02-15
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S190100, C424S193100
Reexamination Certificate
active
06855320
ABSTRACT:
Methods for enhancing the immunogenicity of an antigen via fusion to a non-hemolytic truncated form of listeriolysin O are provided.
REFERENCES:
patent: 5262177 (1993-11-01), Brown et al.
patent: 5830702 (1998-11-01), Portnoy et al.
patent: WO 9910496 (1999-04-01), None
Verma et al, Vaccine 13(2): 142-50. Feb 1995.*
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.*
Stryer et al, in Biochemistry, Third edition, W H Freeman Company, New York, pp. 31-33, 1998.*
Mikayama et al, Molecular cloning and functional expression of a cDNA encoding gycosylation-inhibiting factor, Nov 1993, Pro Natl. Acad. Sci, USA vol. 90: 10056-10060.*
Skolnick et al., From genes to protein structure and function: novel applications of computational approaches in the genomic era, Jan 2000, Trends in Biotech. 18(1): 34-39.*
Makela et al, Hand book of Experimental Immunology vol. 1, chapter 3, pp. 3.1-3.13; 1987.*
Safley et al, J Immunology 146(10): 3604-3616; May 1991.*
Bielecki J. et al., “Bacillus subtilisexpressing a haemolysin gene from Listeria monocytogenes can grow in mammalian cells”,Nature1990 345:175-176.
Gentschev et al., “SalmonellaStrain Secreting Active Listeriolysin Changes Its Intracellular Localization”,Infect. Immun. 1995 63:4202-4205.
Ikonomidis et al., “Delivery of a Viral Antigen to the Class I Processing and Presentation pathway byListeria monocytogenes”, J. Exp. Med. 1994 180:2209-2218.
Kaufmann, S.H. and Hess,J., “Impact of intracellular location of and antigen display by intracellular bacteria: implications for vaccine development”,Immunol. Lett. Jan. 1999 65(1-2):81-4.
Lin et al., “Treatment of Established Tumors with a Novel Vaccine That Enhances Major Histocompatibility Class II Presentation of Tumor Antigen1”,Cancer Res. 1996 56:21-6.
Pan et al., “Regression of Established Tumors in Mice Mediated by the Oral Administration of a RecombinantListeria monocytogenesVaccine1”,Cancer Res. 55:4776-4779.
Tanabe et al., “Induction of Protective T cells againstListeria monocytogenesMice by Immunization with a Listeriolysin O-Negative Avirulent Strain of Bacteria and Liposome-Encapsulated Listeriolysin O”, J. Immunology 67(2): 568-575, 1999.
Wu et al., “Engineering an itracellular pathway for major histocompatibility complex class II presentation of antigens”,Proc. Natl. Acad. Sci. USA1995 92:11671-5.
Chan Christina
Huynh Phuong
Morgan & Lewis & Bockius, LLP
The Trustees of the University of Pennsylvania
LandOfFree
Fusion of non-hemolytic, truncated form of listeriolysin O... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fusion of non-hemolytic, truncated form of listeriolysin O..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion of non-hemolytic, truncated form of listeriolysin O... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3487813